Lv5
810 积分 2022-04-26 加入
Mechanisms and Strategies of Immunosenescence Effects on Non-Small Cell Lung Cancer (NSCLC) Treatment: A Comprehensive Analysis and Future Directions
7小时前
待确认
Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
7小时前
已完结
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
1个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1个月前
已完结
Real world safety of bevacizumab in cancer patients: A systematic literature review of case reports
2个月前
已完结
An open-label, single-arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR-positive, HER2-negative advanced breast cancer patients: BRIGHT-1 trial
2个月前
已完结
The next generation of immunotherapies for lung cancers
2个月前
已完结
Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer
2个月前
已完结
Efficacy of immune checkpoint inhibitors (ICIs) in PD-L1 negative non-small cell Lung cancer (NSCLC) – A meta-analysis based on reconstructed individual participant data
3个月前
已完结
Efficacy of nivolumab + ipilimumab ± chemotherapy versus pembrolizumab + chemotherapy in patients with PD-L1-negative non-small cell lung cancer (START001 PART-B): a multicenter retrospective observational study
3个月前
已完结
皖公网安备34019202002308
